Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study
Among patients initiating semaglutide for weight management, semaglutide did not appear to increase the risk of suicide-related outcomes. However, the CIs of the RDs are compatible with a 0.07% increase in 6-month risk and the true RD could be larger due to the potentially low sensitivity of ICD-10 diagnosis codes for and underreporting of suicide-related outcomes. Additional studies are critical to confirm these findings and obtain more precise estimates of any potential benefits or harms of semaglutide.
Authors
- John B. Buse (ORCID: https://orcid.org/0000-0002-9723-3876)
- Michael Webster‐Clark (ORCID: https://orcid.org/0000-0002-8079-8504)
- Til Stürmer (ORCID: https://orcid.org/0000-0002-9204-7177)
- Virginia Pate
- Michele Jönsson Funk (ORCID: https://orcid.org/0000-0002-3756-7540)
- Qoua L. Her (ORCID: https://orcid.org/0000-0002-6427-1032)
- Tiansheng Wang
Institutions
- University of North Carolina at Chapel Hill (US)
- Wake Forest University (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1111/dom.70002
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Division of Cancer Prevention, National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases